CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. files a definitive proxy statement for its 2026 Annual Meeting and highlights 2025 operational results, the August 2025 acquisition of Melinta Therapeutics LLC, and several charter and governance proposals for stockholder approval.
Management reports $311.7 million total 2025 revenue, including $258.8 million in DefenCath net sales and $52.9 million from the partial-year Melinta portfolio, and $163.0 million net income ($2.04 per diluted share). The virtual Annual Meeting is scheduled for June 23, 2026 with record date April 24, 2026. Key proposals include ratification of certain preferred-stock certificate amendments, charter technical updates, a class-voting change, exclusive-forum designation, officer liability updates, director elections, say-on-pay, auditor ratification and an adjournment proposal.
CorMedix Inc: The Vanguard Group filed an amendment to its Schedule 13G reporting that, after an internal realignment, certain Vanguard subsidiaries will report holdings separately and The Vanguard Group now reports 0 shares and 0% ownership of CorMedix common stock as of the amendment. The filing explains the disaggregation is in accordance with SEC Release No. 34-39538 and is signed by Vanguard's Head of Global Fund Administration on 03/26/2026.
CorMedix Inc. furnished an updated investor presentation and reaffirmed its prior guidance that full-year 2027 DefenCath sales are estimated at $100–$140 million, clarifying an inadvertent reference to $100–$125 million on a recent earnings call. The presentation outlines a broader growth plan, including 2026 revenue guidance of $300–$320 million and adjusted EBITDA of $100–$125 million, driven by DefenCath and a diversified anti-infective portfolio. Pro forma 2025 net revenue is shown at $401 million, with Q4 2025 DefenCath sales of $91 million and 79.1 million common shares outstanding as of December 31, 2025. CorMedix also highlights late-stage expansion opportunities for DefenCath in total parenteral nutrition and for REZZAYO in fungal prophylaxis, alongside a cash and short-term investment balance of $149 million.
CorMedix Inc. reports a transformational 2025, moving to net income of $163.1 million from a $17.9 million loss in 2024, while carrying an accumulated deficit of $176.6 million as of December 31, 2025.
Growth is led by DefenCath, its first-in-class antimicrobial catheter lock, launched across U.S. hemodialysis settings in 2024 and now the largest contributor to net sales. The August 2025 acquisition of Melinta Therapeutics adds six marketed hospital anti-infectives plus cardiovascular drug TOPROL-XL, creating a broader acute-care portfolio.
DefenCath benefits from Medicare NTAP and ESRD TDAPA, but reimbursement will reset as NTAP ends in November 2026 and TDAPA shifts to a post-TDAPA add-on in July 2026, which the company expects to pressure net pricing in late 2026. CorMedix is also investing in label expansion for DefenCath and REZZAYO and advancing BARDA-supported pediatric and biothreat programs while relying on third-party manufacturing and extensive intellectual property and exclusivity protections.
CorMedix Inc. reported a strong finish to 2025, with fourth-quarter net revenue of $128.6 million, including $91.2 million from DefenCath and $37.4 million from the newly acquired Melinta portfolio, up sharply from $31.2 million in the prior-year quarter.
For full-year 2025, total revenue rose to $311.7 million and pro forma revenue, assuming a full year of Melinta, reached $401.3 million. The company generated net income of $163.1 million, or $2.04 per diluted share, reversing a $17.9 million loss in 2024, and delivered adjusted EBITDA of $77.2 million in Q4 2025. Operating expenses roughly doubled as CorMedix absorbed Melinta and invested in DefenCath and late-stage studies, while cash, cash equivalents and short-term investments totaled $148.5 million as of December 31, 2025.
CorMedix Inc. insider filing shows a new equity award to its Chief Legal Officer. Beth Zelnick Kaufman received 36,006 shares of common stock on February 4, 2026 at a price of $0.00, following achievement of performance stock unit (PSU) goals for the first of three performance periods.
The PSUs were originally granted on January 2, 2025 and remain subject to additional time-based vesting conditions before fully vesting. After this award, she beneficially owns 269,108 shares of CorMedix common stock directly.
CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported an equity-related award linked to performance stock units. On 02/04/2026, she acquired 36,006 shares of CorMedix common stock at a reported price of $0.00, increasing her beneficial ownership to 278,539 directly held shares.
The filing explains this reflects achievement of performance stock units granted on January 2, 2025, after the Compensation Committee determined that performance conditions for the first of three performance periods were met. These units remain subject to additional time-based vesting requirements for Hurlburt.
CorMedix Inc. reported an equity award to its Chief Executive Officer and director Joseph Todisco. On February 4, 2026, he acquired 77,156 shares of common stock at $0.00 per share, following the achievement of performance stock units for the first of three performance periods granted on January 2, 2025.
After this transaction, Todisco beneficially owned 774,749 shares of CorMedix common stock, held directly. The performance stock units remain subject to time-based vesting conditions that must be satisfied by the reporting person before full vesting.
CorMedix Inc. Chief Financial Officer Susan Blum reported equity compensation and related share withholding transactions. On 01/23/2026, she was granted 72,820 restricted stock units, each representing one share of CorMedix common stock at a stated price of $0.00.
The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, 9,767 shares of common stock were disposed of at $7.27 per share in a transaction coded "F," typically indicating shares withheld to cover taxes. After these transactions, Blum directly owned 132,739 shares of CorMedix common stock.
CorMedix Inc.'s Chief Legal Officer Beth Zelnick Kaufman reported equity compensation activity in the company’s common stock. On 01/23/2026 she received an award of 72,820 restricted stock units at a price of $0.00 per unit, each representing one share of common stock.
The restricted stock units vest 25% on the grant date and, subject to continued employment, 25% on each of the first, second, and third anniversaries of the grant date. On the same day, 8,803 shares were withheld at $7.27 per share, typically for tax obligations, leaving her with 233,102 directly owned shares after the reported transactions.